Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from PFE

Pfizer's Paxlovid Becomes First Oral COVID-19 Therapy To Be Evaluated In Pediatric Clinical Study

Pfizer Inc (NYSE: PFE) has initiated a Phase 2/3 EPIC-PEDS trial to evaluate Paxlovid (nirmatrelvir and ritonavir tablets)

Pfizer Commits 10M Courses Of COVID-19 Oral Antiviral To Developing Countries: Reuters

Pfizer Commits 10M Courses Of COVID-19 Oral Antiviral To Developing Countries: Reuters

Pfizer Inc (NYSE:PFE) is expected to provide around 10 million courses of its highly effective COVID-19 antiviral treatment Paxlovid to low- and middle-income countries in 2022, reports Reuters citing an official with the Global Fund. The Fund's head of strategy for policy, Harley Feldbaum, said Pfizer had committed at least that many…

Pfizer/BioNTech's COVID-19 Vaccine Mere 12% Effective In Kids 5-11 Years, New York Study Shows

Pfizer/BioNTech's COVID-19 Vaccine Mere 12% Effective In Kids 5-11 Years, New York Study Shows

According to a published study, Pfizer Inc (NYSE: PFE) and BioNTech SE's (NASDAQ: BNTX) two-dose COVID-19 vaccine provided very little protection for children aged 5 to 11 years during the wave of o

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Pfizer's Clostridioides Difficile Vaccine Fails To Prevent C. Difficile Infection

Pfizer Inc (NYSE: PFE) announced data from the CLOVER Phase 3 trial evaluating Clostridioides difficile vaccine candidate to prevent C. difficile infection (CDI).

5 High-Quality Mega-Cap Stocks to Scoop Up Now

In addition to inflationary pressure, economic sanctions imposed on Russia by various countries and corporations in response to Russia’s invasion of Ukraine have exacerbated volatility in the global markets. As investors seek to avoid that volatility and generate stable returns, we think high-quality mega-cap stocks Pfizer (PFE), Cisco (CSCO), Abbott…

Longer Waiting Period Between mRNA COVID-19 Doses May Cut Heart Inflammation Risk, CDC Suggests

The Centers for Disease Control and Prevention said that younger males should consider waiting longer between doses of Pfizer Inc's (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna

Pfizer/BioNTech's Omicron-Targeted COVID-19 To Miss March Timeline: Reuters

Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) omicron-targeted COVID-19 vaccine is delayed by several weeks due to a slower-than-expected data gathering process,

inkl

Read news from The Economist, FT, and more,
with one subscription

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Forget AstraZeneca, Buy These 4 Pharmaceutical Stocks Instead

Despite the rising demand for COVID-19 vaccines and other pharmaceutical products, AstraZeneca (AZN) has failed to deliver impressive earnings in its last quarter. While its recent drug launches are expected to do well in the long run, the consensus earnings estimate for the company in the current quarter indicates tepid…

Pfizer, Moderna COVID-19 Boosters Effectiveness Wanes After Four Months: CDC Study

Pfizer, Moderna COVID-19 Boosters Effectiveness Wanes After Four Months: CDC Study

COVID-19 vaccine boosters from Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) and Moderna Inc (NASDAQ:

Expert Ratings For Pfizer

Expert Ratings For Pfizer

Analysts have provided the following ratings for Pfizer (NYSE:PFE) within the last quarter:

Pfizer Q4 Sales Lag Consensus; Forecasts $54B In FY22 From COVID-19 Vaccine, Treatment Pill

Pfizer Q4 Sales Lag Consensus; Forecasts $54B In FY22 From COVID-19 Vaccine, Treatment Pill

Pfizer Inc (NYSE: PFE) has reported

5 Stocks To Watch For February 8, 2022

5 Stocks To Watch For February 8, 2022

Some of the stocks that may grab investor focus today are: Wall Street expects Pfizer Inc. (NYSE: PFE) to report quarterly earnings at $0.87 per share on revenue of $24.20 billion before the opening bell. Pfizer shares rose 1.7% to $54.10 in after-hours trading.

Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva - Pfizer Choose Three-Dose Schedule For Lyme Vaccine Candidate Moving Forward

Valneva SE (NASDAQ: VALN) and Pfizer Inc (NYSE: PFE) have

FDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children

FDA Asks Pfizer - BioNTech To Submit For COVID-19 Vaccine Emergency Use Nod For Youngest Children

Pfizer Inc (NYSE: PFE) and its partner BioNTech SE (NASDAQ: BNTX) have

Get all your
news in one place.

100's of premium titles.
One news app.

Pfizer, BioNTech Launch Omicron-Targeted COVID-19 Vaccine Trial

Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have

Check Out What Whales Are Doing With PFE

Someone with a lot of money to spend has taken a bearish stance on Pfizer (NYSE:PFE). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

3 Pharmaceutical Stocks to Buy for the Long-Term

The global pharmaceutical industry is expected to witness stable growth over the long term, owing to the rising medical needs of an aging population and consistent innovations in the treatment of chronic ailments. So, we think it could be wise to scoop up shares of quality pharmaceutical stocks Johnson &…

Pfizer's COVID-19 Oral Antiviral Shows In-Vitro Efficacy Against Omicron Variant

Pfizer Inc (NYSE: PFE) yesterday

Get all your
news in one place.

100's of premium titles.
One news app.

1 … 11 12 13 14

Organisations

Johnson & Johnson (

Centers for Disease Control and Prevention

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

367,427 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play